Galera Therapeutics, Inc. (GRTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 84 | |||
| General and administrative | 1,051 | |||
| Loss from operations | -1,135 | |||
| Interest income | 60 | |||
| Foreign currency loss | - | |||
| Change in fair value of warrant liability | - | |||
| Net loss | -1,075 | |||
| Net loss per share of common stock, basic | - | |||
| Net loss per share of common stock, diluted | - | |||
| Weighted average number of shares outstanding, diluted | 98,503,430 | |||
| Weighted-average shares of common stock outstanding, basic | 98,503,430 | |||